Association of neutrophil percentage-to-albumin ratio with all-cause and respiratory disease-related mortality in US adults with asthma: results from NHANES 1999-2018

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background: Systemic inflammation and immune dysregulation may be associated with asthma onset and progression. Neutrophil percentage-to-albumin ratio (NPAR) is a novel marker of systemic inflammation. We aimed to investigate the association of NPAR with all-cause and respiratory disease-related mortality in adults with asthma through NHANES 1999-2018. Methods: NPAR was calculated by neutrophil percentage (% of total white blood cell count) × 100/serum albumin (g/dl). Asthma was diagnosed by standardized questionnaire. Mortality was obtained by prospective matching with the National Death Index. Multivariate Cox proportional hazards regression analysis was used to explore these associations. Results: A total of 5042 adults with asthma were included. After a median follow-up duration of 104 months, 697 participants died, of which 101 were respiratory disease-related deaths. In fully adjusted models, NPAR was significantly and positively associated with both all-cause and respiratory disease-related mortality (hazard ratios [HR] of 1.126 and 1.194, respectively, both p < 0.05). Compared to Q1, NPAR at Q4 was associated with significantly increased all-cause and respiratory disease-related mortality (all-cause: HR 2.112, p < 0.0001; respiratory disease-related: HR 2.595, p = 0.013). NPAR was nonlinearly associated with all-cause mortality, with an inflection point of 13.76. This association was significant only after the inflection point. The effect of NPAR on all-cause mortality was more pronounced in those <60 years of age. Conclusions: Higher NPAR was associated with increased all-cause and respiratory disease mortality in US adults with asthma. Further exploration of the prognostic potential and underlying mechanisms of NPAR is needed. Clinical trial number Not applicable.

Article activity feed